Abstract 173P
Background
In the phase III RESORCE trial, regorafenib improved overall survival (OS) vs placebo in pts with uHCC who progressed on sorafenib. The international, prospective REFINE study was designed to evaluate regorafenib in pts with uHCC in routine practice. We present interim results for pts enrolled in REFINE in Korea, China, and Taiwan.
Methods
REFINE is an ongoing observational study that recruited patients with uHCC for whom a decision to treat with regorafenib was made by the treating physician prior to enrollment according to the local health authority approved label. A planned interim analysis was performed when the first 500 pts in the global cohort had been observed for ≥4 months. The primary aim is to assess treatment-emergent adverse events (TEAEs; NCI-CTCAE v4.03). Secondary endpoints include OS, progression-free survival, and tumor response. Tumor response and progression are assessed per investigator according to local standard.
Results
In the interim analysis, a total of 182 pts were enrolled from Korea (n=127; 70%), China (n=48; 26%), and Taiwan (n=7; 4%). The median age was 60 years (range 21–90); 80% were male. At study entry, proportions of pts with ECOG performance status 0/1/≥2 were 37%/49%/5%; proportions with Child–Pugh A/B/C class were 70%/5%/1% (missing/not evaluable: 24%). The initial daily regorafenib dose was 160 mg in 70% of pts and 120 mg/80 mg in 14%/15%; 1 pt started at 40 mg. The mean initial daily dose was 142 mg (standard deviation 31). Median treatment duration was 3.2 months (interquartile range 1.9–9.3). The most frequent TEAEs (reported in ≥5% patients) are shown in the table. Effectiveness results will be presented.
Conclusions
In this interim analysis of pts from Asia in the observational REFINE study, the TEAEs reported were consistent with those reported in the phase III RESORCE trial, although incidence rates of some TEAEs were lower than in RESORCE Table: 173P
TEAE, % | Regorafenib (n=182) | ||
Any grade | Grade 3 | Grade 4 | |
Hand–foot skin reaction | 29 | 1 | - |
Diarrhea | 14 | 2 | 0 |
Decreased appetite | 9 | 1 | 0 |
Abdominal pain | 7 | 3 | 0 |
Hypertension | 6 | 2 | 0 |
Fatigue | 5 | 1 | - |
Clinical trial identification
NCT03289273.
Editorial acknowledgement
Editorial assistance in the writing of this abstract was provided by Jennifer Tobin of OPEN Health Medical Communications (Choice), with financial support from Bayer.
Legal entity responsible for the study
Bayer.
Funding
Bayer.
Disclosure
H.Y. Lim: Advisory/Consultancy: Bayer; Advisory/Consultancy: Ipsen; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy: Eisai; Advisory/Consultancy: Ono Pharmaceutical. Y.J. Kim: Honoraria (self): Eisai; Honoraria (self), Advisory/Consultancy: AbbVie; Honoraria (self), Advisory/Consultancy, Research grant/Funding (self): Bristol-Myers Squibb; Honoraria (self), Research grant/Funding (self): BTG; Honoraria (self): Bayer; Honoraria (self): MSD; Honoraria (self), Advisory/Consultancy, Resarch grant/Funding (self): Gilead Sciences; Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): Roche. Y-H. Huang: Advisory/Consultancy: Gilead Sciences; Advisory/Consultancy: Bristol-Myers Squibb; Advisory/Consultancy: MSD; Advisory/Consultancy: Bayer. C-H. Hsu: Honoraria (self), Advisory/Consultancy: Bristol-Meyers Squibb; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Ono Pharmaceutical; Honoraria (self), Advisory/Consultancy, Research grant/Funding (institution), Travel/Accommodation/Expenses: MSD; Honoraria (self), Advisory/Consultancy, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy: Lilly; Advisory/Consultancy: Genentech; Advisory/Consultancy: Merck Serono. H.C. Lee: Advisory/Consultancy, Research grant/Funding (self): AstraZeneca; Research grant/Funding (self): Bayer; Research grant/Funding (self): Roche; Research grant/Funding (self): Merck; Research grant/Funding (self): Bristol-Myers Squibb. S. Fiala-Buskies: Shareholder/Stockholder/Stock options, Full/Part-time employment: Bayer. S. Kapur: Full/Part-time employment: Bayer. All other authors have declared no conflicts of interest.
Resources from the same session
276P - Sarcopenia to predict overall survival in head and neck cancer patients receiving chemotherapy: A systematic review and meta-analysis
Presenter: Felix Kwenandar
Session: e-Poster Display Session
277P - Tegafur/uracil, platinum and cetuximab (UPEx) as first line treatment in frail patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Meng-che Hsieh
Session: e-Poster Display Session
278P - Serial assessment of parotid volume changes during radical chemoradiation of locally advanced head and neck cancer: Its implications in practice of adaptive radiotherapy
Presenter: Aathira T S
Session: e-Poster Display Session
279P - Clinico pathological characteristics and survival outcome in oral cavity cancer with masticator space involvement (T4b): A retrospective single institutional experience
Presenter: Abdulla Kunnummal Palathinkara
Session: e-Poster Display Session
280P - Safety and efficacy of concurrent chemoradiotherapy for head and neck cancers in younger versus older patients: Post hoc analysis of a randomized control trial
Presenter: Vanita Noronha
Session: e-Poster Display Session
281P - Prevalence of premalignant lesions and oral cancer among tobacco-using tea plantation workers of Nilgiri Hills, Tamilnadu, India
Presenter: Delfin Lovelina Francis
Session: e-Poster Display Session
282P - Filipino head and neck cancer patients and their quality of life
Presenter: Frederic Ivan Ting
Session: e-Poster Display Session
283P - Descriptive epidemiology of head and neck cancer in Niger: First results from the National Cancer Registry
Presenter: Salamatou Mamoudou Garba
Session: e-Poster Display Session
284P - Outcomes of metronomic adjuvant chemotherapy with tegafur-uracil in locally advanced head and neck squamous cell carcinoma
Presenter: Tsung-jang Yeh
Session: e-Poster Display Session
285P - Comparison of induction chemotherapy plus concurrent chemoradiotherapy and concurrent chemoradiotherapy alone in locally advanced nasopharyngeal carcinoma: A meta-analysis
Presenter: Xu Guoqiang
Session: e-Poster Display Session